CN1548413A - Beta-diketoacid as dimer compound and its prepn and use - Google Patents
Beta-diketoacid as dimer compound and its prepn and use Download PDFInfo
- Publication number
- CN1548413A CN1548413A CNA031167586A CN03116758A CN1548413A CN 1548413 A CN1548413 A CN 1548413A CN A031167586 A CNA031167586 A CN A031167586A CN 03116758 A CN03116758 A CN 03116758A CN 1548413 A CN1548413 A CN 1548413A
- Authority
- CN
- China
- Prior art keywords
- beta
- compound
- aryl
- acid dimer
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 43
- 239000000539 dimer Substances 0.000 title claims abstract description 34
- 239000002253 acid Substances 0.000 claims abstract description 44
- -1 diphenyl ethyl Chemical group 0.000 claims abstract description 16
- LUJMEECXHPYQOF-UHFFFAOYSA-N 3-hydroxyacetophenone Chemical compound CC(=O)C1=CC=CC(O)=C1 LUJMEECXHPYQOF-UHFFFAOYSA-N 0.000 claims abstract description 12
- 230000008878 coupling Effects 0.000 claims abstract description 7
- 238000010168 coupling process Methods 0.000 claims abstract description 7
- 238000005859 coupling reaction Methods 0.000 claims abstract description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 5
- 230000007062 hydrolysis Effects 0.000 claims abstract description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000003513 alkali Substances 0.000 claims abstract description 3
- 150000004985 diamines Chemical class 0.000 claims abstract description 3
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 claims abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N methyl alcohol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 11
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 150000002576 ketones Chemical class 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 208000030507 AIDS Diseases 0.000 claims description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 5
- VCJZTATVUDMNLU-UHFFFAOYSA-N dibromomethylbenzene Chemical compound BrC(Br)C1=CC=CC=C1 VCJZTATVUDMNLU-UHFFFAOYSA-N 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 4
- KRIOVPPHQSLHCZ-UHFFFAOYSA-N propiophenone Chemical class CCC(=O)C1=CC=CC=C1 KRIOVPPHQSLHCZ-UHFFFAOYSA-N 0.000 claims description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 3
- YHPUKWSIJCYFLM-UHFFFAOYSA-N 2-o-tert-butyl 1-o-methyl oxalate Chemical class COC(=O)C(=O)OC(C)(C)C YHPUKWSIJCYFLM-UHFFFAOYSA-N 0.000 claims description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 3
- LOMVENUNSWAXEN-UHFFFAOYSA-N Methyl oxalate Chemical compound COC(=O)C(=O)OC LOMVENUNSWAXEN-UHFFFAOYSA-N 0.000 claims description 3
- 125000005002 aryl methyl group Chemical group 0.000 claims description 3
- 239000003518 caustics Substances 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 239000003810 Jones reagent Substances 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 230000031709 bromination Effects 0.000 claims description 2
- 238000005893 bromination reaction Methods 0.000 claims description 2
- LIKFHECYJZWXFJ-UHFFFAOYSA-N dimethyldichlorosilane Chemical compound C[Si](C)(Cl)Cl LIKFHECYJZWXFJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 2
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 108700020129 Human immunodeficiency virus 1 p31 integrase Proteins 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 230000004913 activation Effects 0.000 abstract 1
- QVFPIKASFQBJDE-UHFFFAOYSA-N toluene;dihydrobromide Chemical compound Br.Br.CC1=CC=CC=C1 QVFPIKASFQBJDE-UHFFFAOYSA-N 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
- 239000000243 solution Substances 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- 239000012074 organic phase Substances 0.000 description 27
- 239000011734 sodium Substances 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- 238000005406 washing Methods 0.000 description 19
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 235000002639 sodium chloride Nutrition 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 13
- 239000012141 concentrate Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 238000013019 agitation Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000003810 ethyl acetate extraction Methods 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 8
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- 239000002850 integrase inhibitor Substances 0.000 description 6
- 229940124524 integrase inhibitor Drugs 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- YDVNLQGCLLPHAH-UHFFFAOYSA-N dichloromethane;hydrate Chemical compound O.ClCCl YDVNLQGCLLPHAH-UHFFFAOYSA-N 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 4
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 4
- KMBNQIVUWJLMIN-UHFFFAOYSA-N 1-benzyl-3-bromobenzene Chemical compound BrC1=CC=CC(CC=2C=CC=CC=2)=C1 KMBNQIVUWJLMIN-UHFFFAOYSA-N 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 229940126543 compound 14 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 125000005594 diketone group Chemical group 0.000 description 4
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 125000003835 nucleoside group Chemical group 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- RRELDGDKULRRDM-UHFFFAOYSA-N 6-[2-chloro-4-nitro-5-(oxan-4-yloxy)anilino]-3,4-dihydro-1H-quinolin-2-one Chemical compound [O-][N+](=O)c1cc(Cl)c(Nc2ccc3NC(=O)CCc3c2)cc1OC1CCOCC1 RRELDGDKULRRDM-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000004342 Benzoyl peroxide Substances 0.000 description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 3
- UUIQMZJEGPQKFD-UHFFFAOYSA-N Methyl butyrate Chemical class CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 description 3
- ANUZKYYBDVLEEI-UHFFFAOYSA-N butane;hexane;lithium Chemical compound [Li]CCCC.CCCCCC ANUZKYYBDVLEEI-UHFFFAOYSA-N 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- DPRJPRMZJGWLHY-HNGSOEQISA-N (e,3r,5s)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)/C=C/C=1C(C(C)C)=NN(C=2N=CC=NC=2)C=1C1=CC=C(F)C=C1 DPRJPRMZJGWLHY-HNGSOEQISA-N 0.000 description 2
- MMZYCBHLNZVROM-UHFFFAOYSA-N 1-fluoro-2-methylbenzene Chemical compound CC1=CC=CC=C1F MMZYCBHLNZVROM-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 2
- MUJNAWXXOJRNGK-UHFFFAOYSA-N n-[3-(6-methyl-1,2,3,4-tetrahydrocarbazol-9-yl)propyl]cyclohexanamine Chemical compound C1=2CCCCC=2C2=CC(C)=CC=C2N1CCCNC1CCCCC1 MUJNAWXXOJRNGK-UHFFFAOYSA-N 0.000 description 2
- YRCHYHRCBXNYNU-UHFFFAOYSA-N n-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=S)NC(=O)CC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 YRCHYHRCBXNYNU-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 150000003509 tertiary alcohols Chemical class 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QKLXBIHSGMPUQS-FGZHOGPDSA-M (3r,5r)-7-[4-(4-fluorophenyl)-2,5-dimethyl-1-phenylpyrrol-3-yl]-3,5-dihydroxyheptanoate Chemical compound CC1=C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C(C)N1C1=CC=CC=C1 QKLXBIHSGMPUQS-FGZHOGPDSA-M 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical group FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 1
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N Cadaverine Natural products NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 238000006809 Jones oxidation reaction Methods 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical compound CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- XVKVDNJOCXUTNN-UHFFFAOYSA-N [Li]C1=CC=CC=C1.Br Chemical compound [Li]C1=CC=CC=C1.Br XVKVDNJOCXUTNN-UHFFFAOYSA-N 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- QABCGOSYZHCPGN-UHFFFAOYSA-N chloro(dimethyl)silicon Chemical compound C[Si](C)Cl QABCGOSYZHCPGN-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940059936 lithium bromide Drugs 0.000 description 1
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Inorganic materials [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- FEKRFYZGYUTGRY-UHFFFAOYSA-N n'-ethylmethanediimine Chemical compound CCN=C=N FEKRFYZGYUTGRY-UHFFFAOYSA-N 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000035892 strand transfer Effects 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The beta-diketo acid dimer compound is prepared through coupling 4-aryl-4-oxy-2-hydroxy-2-butenic acid and diamine in different structure under the activation of coupling reagent to obtain diketo acid diamide, or reacting toluene dibromide and 3-hydroxy acetophenone under alkali condition to obtain benzyloxy radical connected diphenyl ethyl ketone; oxalylation and hydrolysis to obtain corresponding diaryl beta-diketo acid dimer. Pharmacological experiment shows that the compound of the present invention has very high HIV-1 integrase inhibiting activity.
Description
Technical field
The present invention relates to have beta-diketon acid dimer synthetic of symmetrical structure, more particularly for containing 3-aryl-1, the dimer compounds of 3-diketone acid mono is as the synthetic purposes that reaches of efficient HIV-1 integrase inhibitor.
Background technology
HIV-1 is the virus that causes acquired immune deficiency syndrome (AIDS), its three kinds of enzyme of encoding: reversed transcriptive enzyme (reversetranscriptase, RT), proteolytic enzyme (protease, PR) and intergrase (integrase, IN).These three kinds of enzymes are that HIV duplicates and infects necessary basic enzyme.The medicine that is used for the treatment of at present acquired immune deficiency syndrome (AIDS) clinically all is reverse transcriptase inhibitors and proteinase inhibitor, but this two classes medicine all can not be eradicated HIV, and side effects such as toxicity, patient's complication and multiple drug resistance have appearred, therefore, integrase inhibitor with novel mechanism of action is expected to improve curative effect, and can act synergistically with existing anti-acquired immunodeficiency syndrome drug deposits yields, form new effective conjoint therapy.HIV-1 intergrase (IN) is one of virus replication necessary three big basic enzyme, and retrovirus DNA inserts in the host chromosome under the catalysis of intergrase, and then duplicating and infecting of HIV taken place; And the HIV-1 intergrase might limit HIV the integrase inhibitor medicine is developed immunity to drugs with single reactive site and virus and two kinds of the hosts DNA substrate-function of isomorphic map not; Intergrase only is present in the virus in addition, and Mammals does not all have this fermentoid, thus the HIV-1 intergrase become big promising inverase design novel target protein (Curr.Opin.Drug Discov.Devel.2001,4,402-410).
Present many synthetic compounds have the effect that suppresses the HIV-1 intergrase, but (Science 2000 to have only the beta-diketon acid compounds to show effective intracellular antiviral activity, 287,646-650), its biological isostere beta-diketon tetrazolium S-1360 has entered the clinical II phase as the HIV-1 integrase inhibitor and has studied.Because the HIV-1 intergrase shows with dimerization or tetramer form and plays katalysis, therefore, we are from the diketone acid compound, the beta-diketon acid dimer that synthesizes different structure by the connection plate of different lengths, orientation, shape, further improve active, increase selectivity, exploitation has the Me Too medicine of antiviral activity.
Summary of the invention
The objective of the invention is to seek the beta-diketon acids dimer compound that a class has the efficient HIV-1 integrase inhibitor of antiviral activity.
Another object of the present invention provides the preparation method of a class beta-diketon acids dimer compound.
A further object of the present invention provides and contains 3-aryl-1, and the dimer compounds of 3-two ketone acids is in medically purposes.
The present invention's design is based on HIV-1 intergrase and interactional crystalline structure of its inhibitor and structure activity relationship, because the HIV-1 intergrase shows with dimerization or tetramer form and plays katalysis (Proc.Natl.Acad.Sci.USA, 1999,96,13040-13043), but the precise nature of oligomer is still unknown, therefore, we are from having the beta-diketon acid compounds of antiviral activity, connection plate by different lengths, orientation, shape synthesizes the beta-diketon acid dimer, to obtain highly active antiviral agent.
The present invention is with 3-aryl-1,3-two ketone acids are monomer, by different tie points be connected the beta-diketon acid dimer (the compound general formula is shown in 1 and 2) that plate synthesizes different structure, measured simultaneously the HIV-1 integrase inhibiting activities of each compound at molecular level.
A class of the present invention contains 3-aryl-1, and the symmetrical dimer compounds of 3-diketone has following structure 1 and 2:
Wherein, X is N, O, heteroatomss such as S
R is C
2-C
6Alkyl or replacement aromatic ring
R
1Be C
2-C
6Alkyl or replacement aromatic ring
Such structural general formula 1 and 2 total basic frameworks are 4-aryl-4-oxygen-2-hydroxyl-2-butylene acid, shown in their the synthetic following reaction formula:
Corresponding aryl methyl ketone and dimethyl oxalate or oxalic acid tert-butyl ester methyl esters react under the alkali condition, and after the condensation, the two ketone acid methyl esters that obtain get 4-aryl-4-oxygen-2-hydroxyl-2-butylene acid through basic hydrolysis.
Two diketone acid dimers of general formula 1 are by following prepared in reaction:
Wherein, the monomer 5 in the general formula 1 is according to document J.Med.Chem.2000, and 43 (26), 4923 method is synthetic.The phenyl aldehyde and the 3-bromo-1-phenyl lithiumbromide that are about to replace react, and obtain (3-bromo-phenyl)-(phenyl of replacement)-methyl alcohol (compound 3), obtain corresponding 3-benzyl phenyl bromine (compound 4) through the triethyl silicane reduction.This bromide by after the lithium saltsization with the effect of acylating reagent N,N-dimethylacetamide, obtain corresponding aryl ketones.Aryl methyl ketone according to method oxalylization recited above again hydrolysis just obtain corresponding monomer 4-aryl-4-oxygen-2-hydroxyl-2-butylene acid.
With the diamines of the corresponding 4-aryl-4-oxygen-2-hydroxyl of above-mentioned gained-2-butylene acid and different structure at coupling reagent I-hydroxybenzotriazole (HOBT) and 1-[3-(dimethylamino) propyl group]-activation of 3-ethyl carbodiimide (EDCI) under coupling become to have two ketone acid diamide of the different carbon chain of symmetrical structure.
Two diketone acid dimers of general formula 2 obtain by following reaction:
At first dimethylbenzene generates dibromomethylbenzene as starting raw material through N-bromo-succinimide bromination, the different positions of gained replace (adjacent-,-or right-) dibromomethylbenzene and 3-hydroxy acetophenone under alkaline condition, react two phenyl ethyl ketones of being connected of benzyloxy.Two phenyl ethyl ketones of above-mentioned gained are after oxalylization, and hydrolysis gets two accordingly aryl diketone acid dimers again.
The methyl that replaces with phenyl is from (3-bromine phenylbenzene)-(substituted-phenyl)-methyl alcohol as the diketone acid dimer of the connection plate of two (4-aryl-4-oxygen-2-hydroxyl-2-butylene acid), by following reaction acquisition:
Earlier by (3-bromo-phenyl)-(substituted-phenyl)-methyl alcohol through the Jones reagent oxidation get corresponding ketone (compound 11) again with the phenyl lithiumbromide that replaces react the tertiary alcohol (compound 12) that replaces of triaryl, the above-mentioned tertiary alcohol through dichlorodimethylsilane reduce two-(3-bromophenyl)-arylmethane (compound 13) accordingly, compound 13 after lithium saltsization with N-methoxyl group-N-methylacetamide react corresponding diaryl ketone-aryl-methane (compound 14).Compound 14 through oxalic acid tert-butyl ester methyl esters in the presence of sodium methylate, carry out oxalylization react compound 15, to separate and be able to the methane that aryl replaces be two aryl diketone acid dimers of connector element to caustic liquor then.
Pharmacological datum shows that this class contains 3-aryl-1, and the symmetrical dimer of 3-diketone has very high HIV-1 integrase inhibiting activities, the 503nhibiting concentration IC of and chain transfer disconnected for 3 ' end-grain cutting of substrate
50All in 6.0-0.02 μ M scope, the inhibition activity of wherein best compound is higher than monomeric compound.
The HIV-1 integrase inhibiting activities
The mechanism of action of HIV-1 intergrase is a two-step reaction: 1) 3 ' end processing (3 ' Processing): intergrase forms stabilized complex in conjunction with the particular sequence in the terminal repetition zone of the length of proviral DNA (LTR), carry out the inscribe nucleosides acidolysis processing of nucleosides 3 ' end then, cut away sequence specifically ... the GT dinucleotides that CAGT-3 ' is terminal, expose 3 ' recessed hydroxyl; 2) chain transfer (Strand Transfer): finished DNA/ intergrase is integrated mixture in advance and is passed nuclear membrane and enter the nucleon center, combine with host's DNA, 3 ' recessed hydroxyl of intergrase catalysis viral DNA embeds in the karyomit(e) of host cell by transesterification reaction then, becomes sophisticated provirus.Therefore, the activity of integrase inhibitor shows to the inhibition of 3 ' tip cut-off of viral DNA or the inhibition of chain transfer, with 503nhibiting concentration IC
50Characterize.
Recombinant protein HIV-1 intergrase is used in the test of external intergrase, according to the method operation of document description (Methods Enzymol.2001,340,624-633 and J.Med.Chem.1997,40,942-951).In 30 ℃ of pre-down cultivations 30 minutes, the ultimate density of the intergrase that control is added is 200nM in reaction buffer for intergrase and inhibitor.Then, add 5 ' of 20nM-end
32The linear oligomer Nucleotide substrate of P-mark continues to cultivate 1 hour.Reaction is by the cancellation of the isopyknic sex change loading dye of adding institute.One five equilibrium sample is loaded in the gel (0.09M Tris-borate, pH8.3,2mM EDTA, 20% polyacrylamide, 8M urea) of 20% denaturing polyacrylamide and goes up through electrophoretic separation.Behind the gel drying, place in the box of the dynamic phosphorus developing of a part device and expose, analyze by molecule dynamic phosphorus developing device then.
Suppressing per-cent is calculated by following formula:
％I＝100×[1-(D-C)/(N-C)]
It is the mark of 19 Nucleotide (3 '-end-grain cutting stopping pregnancy thing) or chain transfer product that C in the formula, N and D represent 21 Nucleotide substrate conversion under the different condition respectively.C wherein, the condition at N and D place is respectively: dna single solely exists, and DNA adds intergrase, and DNA adds that intergrase adds inhibitor.503nhibiting concentration IC
50Measure the pairing concentration of generation 50% inhibition and determine suppressing the per-cent mapping by inhibitor concentration.
Consisting of of reaction buffer: 25mM MOPS, pH7.2,50mM NaCl, 1mM HEPES, pH7.5,50 μ M EDTA, 50 μ M dithiothreitol (DTT), 7.5mM MnCl
2, 0.1mg/mL bovine serum albumin (BSA), 10.0mM 2 mercapto ethanol, 10% methyl-sulphoxide.
Table 1. has the inhibition activity of the dimer beta-diketon amides 1a-1e of symmetrical structure to wild shape HIV-1 intergrase
IC
50，μM
Compound R R
13 '-cut-out chain transfer
21 nucleosides DNA, 19 nucleosides DNA
At Mn
2+Ion exists down
1a
3.0 0.03 0.8
1b
10.0 0.04，0.175 3.0
1c
7.0 0.045，0.37 2.0
1d
6.5 0.1，1.0 0.37
1e
7-OH (monomer) 3.0 0.37 0.8
Table 2. has the inhibition activity of the dimer beta-diketon amides 1a-1e of symmetrical structure to the HIV-1 intergrase of fixed point variation
IC
50，μM(C-65-S?IN) IC
50，μM(C-56-S?IN)
Compound R R
1
3 '-cut-out chain transfer 3 '-cut-out chain transfer
At Mn
2+Ion exists down
1a
1.25，3.0 0.12，0.08 1.1，2.0 0.2，0.04
1b
3.0，4.0 0.45，0.08 4.5，3.0 0.25，0.1
1c
5.0，＞4.0 0.25，0.05 ＞3.3，4.0 0.85，2.0
1d
3.0，＞3.3 1.0，1.0 2.5，3.3 0.3，0.1
1e
7-OH (monomer) 0.45,＞1.0 0.02, and 0.08 2.0,2.0 0.2,0.04
Table 3. has the inhibition activity of the beta-diketon acid dimer compounds 2a-2d of symmetrical structure to the HIV-1 intergrase of wild shape and fixed point variation
IC
50，μM(WT?IN) IC
50，μM(C-65-S?IN)
Compound R
3 '-cut-out chain transfer 3 '-cut-out chain transfer
At Mn
2+Ion exists down
2a
1.1 1.5 2.5 0.5
2b
6.0，6.0 5.5 10 0.37
2c
1.33，2.0 2.0 1.75 1.75
2d
1.1 2.5 2.5 0.3
7
3.0 0.8 0.45，1.0 0.02，0.08
Embodiment
Below in conjunction with embodiment the present invention is further described, but does not limit the present invention.
Example 1 4-[3-(2-fluoro-benzyl)-phenyl]-2-hydroxyl-4-oxygen-but-2-ene acyl piperazine diamines 1a
Step 1:(3-bromo-phenyl)-(2-fluoro-phenyl)-methyl alcohol (compound 3)
Under nitrogen protection; hexane solution (the 6.5mL that in a dry reaction bottle, adds the n-Butyl Lithium of 1.6M; 10.4mmol) and the 20mL anhydrous tetrahydro furan, be chilled to-78 ℃, with 1; 3-dibromobenzene (1.2mL; 10.0mmol) slowly drop in the system ,-78 ℃～-50 ℃ were stirred 2.5 hours down, then with adjacent fluorobenzaldehyde (1.06mL; 10.4mmol) slowly drop in the system, keep system temperature to be lower than-50 ℃.-78 ℃～-50 ℃ were stirred 0.5 hour, were warming up to room temperature naturally, continued to stir the saturated NH of system 3 hours
4The cancellation of Cl solution, extracted with diethyl ether merges organic layer, uses saturated NaHCO successively
3Solution, saturated common salt water washing, anhydrous Na
2SO
4Dry.Concentrate, column chromatography (petroleum ether/ethyl ether=15: 1) purifying gets 2.82g yellow oil 3, productive rate 95%.
1HNMR(400MHz，CDCl
3)：δ7.59(s，1H)；7.39-7.53(m，2H)；7.20-7.27(m，2H)；7.10-7.19(m，2H)；6.95-7.03(m，1H)；6.02(d，1H)；2.83(d，1H).
Step 2:(3-bromo-phenyl)-(2-fluoro-phenyl)-methane (compound 4)
Under nitrogen protection, (1.183g, 4.21mmol), (0.81mL 5.05mmol) and the 15mL anhydrous methylene chloride, is chilled to 0 ℃, with BF to triethyl silicane to add compound 3 in a dry reaction bottle
3Et
2(0.64mL 5.05mmol) slowly drops in the system O, is warming up to stirred overnight at room temperature naturally, and system is with saturated NaHCO
3The solution cancellation, extracted with diethyl ether merges organic phase, with saturated salt washing, anhydrous Na
2SO
4Dry.Concentrate, column chromatography (100% sherwood oil) purifying gets 0.971g yellow oil 4, productive rate 84%.
1HNMR(400MHz，CDCl
3)：δ7.30-7.35(m，2H)；7.00-7.20(m，6H)；3.95(s，2H).
Step 3:1-[3-(2-fluoro-benzyl)-phenyl] ethyl ketone (compound 5)
With compound 4 (0.67g; 2.53mmol) be dissolved in the 10mL anhydrous tetrahydro furan; be chilled to-78 ℃; under nitrogen protection; the n-Butyl Lithium hexane solution of slow dropping 1.6M in system (1.9mL, 3.0mmol) ,-78 ℃ were stirred 2 hours down; with N; (0.35mL 3.8mmol) slowly drops in the system N-N,N-DIMETHYLACETAMIDE, and temperature of reaction is controlled at below-50 ℃; stirred 0.5 hour down in-78 ℃～-50 ℃; the system HCl solution cancellation of 1N, the water extracted with diethyl ether merges organic phase; the saturated common salt water washing, anhydrous Na
2SO
4Dry.Concentrate, resistates gets 0.288g yellow oil 5, productive rate 63% with column chromatography (petrol ether/ethyl acetate=10: 1) purifying.
1HNMR(400MHz，CDCl
3)：δ7.77-7.83(m，2H)；7.19-7.37(m，2H)；7.15-7.19(m，2H)；7.03-7.14(m，2H)；4.04(s，2H)；2.57(s，3H).
EI-MS(M/Z，％)：228(M
+，39.0)，213(100)，185(10.0)，165(26.0).
Step 4:4-[3-(2-fluoro-benzyl)-phenyl]-2,4-dioxy-methyl-butyrate (compound 6)
Under nitrogen protection, in a dry reaction bottle, add sodium methylate (2.91g, 53.95mmol) and the 45mL dry toluene; be chilled to 0 ℃, will (3.18g, 26.97mmol) dimethyl oxalate reaches (2.461g; 10.79mmol) the ethylene glycol dimethyl ether solution 45mL of compound 5 slowly drops in the system, 0 ℃ was stirred 0.5 hour, and was warming up to 60 ℃ gradually; stirring is spent the night; the system HCl solution cancellation of 1N, the water ethyl acetate extraction merges organic phase; saturated salt washing, anhydrous Na
2SO
4Dry.Concentrate yellow oil 6, not purifiedly directly carry out next step reaction.
EI-MS(M/Z，％)：314(M
+，8.0)，255(100)，213(58.0)，185(10.0)，165(18.0)，109(40.0).
Step 5:4-[3-(2-fluoro-benzyl)-phenyl]-2-hydroxyl-4-oxygen-but-2-ene acid (compound 7)
Previous step gained crude product compound 6 is dissolved in 40mL tetrahydrofuran (THF)/methyl alcohol (1: 1) mixed solvent, under the room temperature condition, drip the sodium hydroxide solution 40mL of 1N, stirring at room 1 hour, the system extracted with diethyl ether, water is transferred pH value to 1～2 with the HCl solution of 2N, uses ethyl acetate extraction then, merge organic phase, use saturated NaHCO successively
3Solution is washed, saturated salt washing, anhydrous Na
2SO
4Dry.Concentrate, residue gets faint yellow cotton-shaped 7, two step of the solid chemical compound yield 53.35% of 1.179g with sherwood oil/methylene dichloride recrystallization purifying.mp117～118℃。
1HNMR(400MHz，CDCl
3)：δ7.88-7.84(m，2H)；7.49-7.42(m，2H)；7.25-7.17(m，2H)；7.15(s，1H)，7.10-7.04(m，2H)；4.08(s，2H).
EI-MS(M/Z，％)：300(M
+，12.5)，255(100)，213(30.0)，183(18.0)，165(26.0)，109(70.0).
Step 6:4-[3-(2-fluoro-benzyl)-phenyl]-2-hydroxyl-4-oxygen-but-2-ene acyl piperazine diamines (compound 1a)
Monomer two ketone acid 4-[3-(2-fluoro-benzyl)-phenyl]-2-hydroxyl-4-oxygen-but-2-ene acid, compound 7 (0.15g, 0.2mmol) and EDCI (0.101g, 0.525mmol), (0.071g 0.525mmol) is dissolved in the 1.5mL anhydrous tetrahydro furan to HOBT, and 0 ℃ was stirred 15 minutes, in system, drip piperazine (0.02g, 0.25mmol) N, dinethylformamide solution 1mL is warming up to room temperature naturally, stir after 2.5 hours, reaction mixture is poured in the frozen water, and the water dichloromethane extraction merges organic phase, with saturated brine washing, anhydrous Na
2SO
4Dry.Concentrate, residue gets brown thickness compound 1a 56mg, productive rate 40% through column chromatography (methylene chloride=60: 1) purifying.
1HNMR(400MHz，CDCl
3)：δ7.79-7.76(m，4H)；7.44-7.38(m，4H)；7.25-7.19(m，2H)；7.17-7.13(m，2H)，7.09-7.03(m，4H)；4.05(s，4H)，3.73-3.78(m，8H).
ESI-MS：651.1(M+H
+，100)，674.2(M+Na
+，12.0).
Target compound 1b-1e makes with similar approach:
Embodiment 2:4-[3-(2-fluoro-benzyl)-phenyl]-2-carboxyl-4-oxygen-but-2-ene acyl quadrol 1b
Pale yellow powder, yield 65%.
1H?NMR(400MHz，CDCl
3)：δ7.87-7.83(m，6H)；7.75-7.42(m，4H)；7.19(s，2H)；7.26-7.02(m，6H)，4.05(s，4H)；3.64(m，4H).
EI-MS(M/Z，％)：323(100)，254(38.0)，213(70.0)，165(26.0)，109(14.0).
Embodiment 3:4-[3-(2-fluoro-benzyl)-phenyl]-2-hydroxyl-4-oxygen-but-2-ene acyl propylene diamine 1c
Pale yellow powder, yield 68%.
1H?NMR(400MHz，CDCl
3)：δ7.88-7.84(m，6H)；7.44-7.38(m，4H)；7.21(s，1H)；7.24-7.13(m，3H)，7.09-7.02(m，3H)；4.06(s，4H)；3.47(q，4H，J＝6.42Hz)；1.8(m，2H).ESI-MS：661.4(M+Na
+，100).
Embodiment 4:4-[3-(2-fluoro-benzyl)-phenyl]-2-hydroxyl-4-oxygen-but-2-ene acyl pentamethylene diamine 1d
Pale yellow powder, yield 70%.
1H?NMR(400MHz，CDCl
3)：δ7.87-7.82(m，4H)；7.44-7.38(m，4H)；7.28-7.25(m，4H)；7.19(s，1H)；7.24-7.13(m，3H)，7.09-7.02(m，3H)；4.06(s，4H)；3.41(q，4H，J＝6.86Hz)；1.69-1.62(m，4H)；1.48-1.40(m，2H).
ESI-MS(M/Z，％)：667.2(M+H
+，96.5)，689.3(M+Na
+，100).
Embodiment 5:4-[3-(2-fluoro-benzyl)-phenyl] 2-hydroxyl-4-oxygen-but-2-ene acyl hexanediamine 1e
Pale yellow powder, yield 70%.mp134～135℃.
1H?NMR(400MHz，CDCl
3)：δ7.87-7.82(m，4H)；7.44-7.38(m，4H)；7.19(s，2H)；7.27-7.13(m，5H)，7.09-7.02(m，3H)，4.06(s，4H)；3.39(q，4H，J＝6.73)，1.63-1.60(m，4H)，1.43-1.40(m，4H).ESI-MS(M/Z，％)：681.3(M+H+，9.0)，703.4(M+Na
+，100).
Embodiment 6:1,2-pair-[3-(1,3-dioxy 3-carboxyl)-Phenoxymethyl]-benzene 2a
Step 1:1,2-pair-brooethyl-benzene (compound 8a)
In an exsiccant list neck bottle, add NBS (6.6g, 37.5mmol), (1.85mL, 15.0mmol) and the 100mL tetracol phenixin, agitation condition adds benzoyl peroxide (18mg) down to o-Xylol.System refluxed 36 hours under intense agitation, during room temperature the sedimentation and filtration that generates in the reaction process was fallen, and filtrate concentrates the back column chromatography, and 100% sherwood oil is made eluent, obtains 1.5g white solid compound 8a, productive rate 33.5%.
1HNMR(400MHz，CDCl
3)：δ4.67(s，4H)，7.30-7.33(m，2H)，7.36-7.39(m，2H)
Step 2:1,2-pair-(3-acetyl Phenoxymethyl)-benzene (compound 9a)
Under nitrogen protection, (0.34g 2.5mmol) is dissolved in the anhydrous N of 4mL, and dinethylformamide is with K with the 3-hydroxy acetophenone
2CO
3(0.71g, 5.14mmol) and compound 8a (0.26g 1.0mmol) adds in the system, system 60 ℃ the reaction 4 hours, behind the system dilute with water, the water ethyl acetate extraction, the merging organic phase, use NaOH solution and the saturated common salt water washing of 2N successively, anhydrous Na
2SO
4Dry.After organic phase concentrated, (PE: EtOAc=3: 1) purifying obtained 0.34g white solid 9a, productive rate 90.9% to the resistates column chromatography.
1HNMR(400MHz，CDCl
3)：δ7.56-7.53(m，6H)，7.42-7.34(m，4H)，7.17-7.15(m，2H)，5.23(s，4H)，2.56(s，6H).
Step 3:1,2-pair-[3-(1,3-dioxy-4 butyric acid methyl esters)-Phenoxymethyl]-benzene (compound 10a)
In the single neck bottle of exsiccant 25mL, add CH
3ONa (167mg, 7.59mmol) and the 1.5mL dry toluene, cryosel is bathed cooling, slowly drip 9a (116mg, 0.31mmol) and MeOOCCOOtBu (198mg 1.24mmol) is dissolved in the solution of THF/DME (3.0mL/3.0mL), 0 ℃ is stirred after 0.5 hour down, under the intense agitation, reaction mixture is poured in the frozen water of HCl solution (1N) into the water dichloromethane extraction, merge organic phase, use the HCl solution of 1N successively, salt washing, anhydrous Na
2SO
4Dry.Organic phase concentrates back resistates column chromatography (CHCl
3/ CH
3OH=10: 1) purifying obtains 0.158g oily compound 10a, productive rate 93.5%.
1HNMR(400MHz，CDCl
3)：δ7.58-7.52(m，6H)，7.44-7.37(m，4H)，7.21-7.18(m，2H)，7.03(s，2H)，5.26(s，4H)，3.94(s，6H).
Step 4:1,2-pair-[3-(1,3-dioxy-3-carboxyl)-Phenoxymethyl]-benzene (compound 2a)
With compound 1,2-is two-and (0.164g 0.30mmol) is dissolved in the mixed solvent (2.0mL: 2.0mL) of tetrahydrofuran (THF) and methyl alcohol to [3-(1,3-dioxy-3-carboxylate methyl ester)-Phenoxymethyl]-benzene 10a, NaOH solution with 3.2mL 1N under the room temperature slowly drops in the system, stir after 1 hour, the reaction system extracted with diethyl ether, water uses the HCl adjust pH of 2N to 1-2, use ethyl acetate extraction then, merge organic phase, salt washing, anhydrous Na
2SO
4Drying.After organic phase concentrated, resistates obtained 0.109g yellow solid 2a, productive rate 70.0%. with sherwood oil/methylene dichloride recrystallization
1HNMR(400MHz，CDCl
3)：δ7.64-7.61(m，3H)；7.59-7.55(m，3H)；7.49-7.45(m，2H)；7.41-7.39(q，2H，J＝13.40)；7.06(s，2H)，5.36(s，4H).
ESI-MS：517.1(M-H
+，38.0)；445.1(100)
Embodiment 7:1,3-pair-[3-(1,3-dioxy-3-carboxyl)-Phenoxymethyl]-benzene 2b
Step 1:1,3-pair-brooethyl-benzene (compound 8b)
In an exsiccant list neck bottle, add NBS (6.68g, 37.5mmol), (1.85mL, 15.0mmol) and the 30mL tetracol phenixin, agitation condition adds benzoyl peroxide (23mg) down to m-xylene.System refluxed 36 hours under intense agitation, during room temperature the sedimentation and filtration that generates in the reaction process was fallen, and filtrate concentrates the back column chromatography, and 100% sherwood oil is made eluent, obtains 1.88g white solid compound 8b, productive rate 47.4%.
1HNMR(600MHz，CDCl
3)：δ4.46(s，4H)，7.40(s，1H)，7.31(m，3H)
Step 2:1,3-pair-(3-acetyl Phenoxymethyl)-benzene (compound 9b)
Under nitrogen protection, (0.5g 3.7mmol) is dissolved in the anhydrous N of 8mL, and dinethylformamide is with K with the 3-hydroxy acetophenone
2CO
3(1.1g, 7.6mmol) and compound 8b (0.40g 1.5mmol) adds in the system, system 60 ℃ the reaction 4 hours, behind the system dilute with water, the water ethyl acetate extraction, the merging organic phase, use NaOH solution and the saturated common salt water washing of 2N successively, anhydrous Na
2SO
4Dry.After organic phase concentrated, (PE: EtOAc=4: 1) purifying obtained 0.41g white solid 9b, productive rate 74.0% to the resistates column chromatography.
1HNMR(400MHz，CDCl
3)：δ2.595(s，6H)，5.14(s，4H)，7.17-7.20(m，2H)，7.36-7.43(m，5H)，7.54-7.58(m，5H).
Step 3:1,3-pair-[3-(1,3-dioxy-4 butyric acid methyl esters)-Phenoxymethyl]-benzene (compound 10b)
In the single neck bottle of exsiccant 25mL, add CH
3ONa (343mg, 6.36mmol) and the 2mL dry toluene, cryosel is bathed cooling, slowly drip 9b (238mg, 0.636mmol) and MeOOCCOOtBu (407mg 2.54mmol) is dissolved in the solution of THF/DME (2.0mL/2.0mL), 0 ℃ is stirred after 0.5 hour down, under the intense agitation, reaction mixture is poured in the frozen water of HCl solution (1N) into the water dichloromethane extraction, merge organic phase, use the HCl solution of 1N successively, salt washing, anhydrous Na
2SO
4Dry.Organic phase concentrates back resistates column chromatography (CHCl
3/ CH
3OH=10: 1) purifying obtains 0.343g oily compound 10b, productive rate 98.7%.
1H?NMR(400MHz，CDCl
3)：δ7.61-7.58(m，4H)，7.56(s，1H)，7.45-7.39(m，5H)，7.24-7.21(m，2H)，7.06(s，2H)，5.16(s，4H)，3.95(s，6H).
Step 4:1,2-pair-[3-(1,3-dioxy-3-carboxyl)-Phenoxymethyl]-benzene (compound 2b)
With compound 1,2-is two-and (0.174g 0.32mmol) is dissolved in the mixed solvent (2.0mL: 2.0mL) of tetrahydrofuran (THF) and methyl alcohol to [3-(1,3-dioxy-3-carboxylate methyl ester)-Phenoxymethyl]-benzene 10b, NaOH solution with 3.2mL1N under the room temperature slowly drops in the system, stir after 1 hour, the reaction system extracted with diethyl ether, water uses the HCl adjust pH of 2N to 1-2, use ethyl acetate extraction then, merge organic phase, salt washing, anhydrous Na
2SO
4Drying.After organic phase concentrated, resistates obtained 0.122g yellow solid 2b, productive rate 73.5% with sherwood oil/methylene dichloride recrystallization.
1HNMR(400MHz，CDCl
3)：δ7.68-7.63(m，4H)，7.51-7.48(m，6H)，7.36-7.33(dd，2H)，7.09(S，2H)，5.23(s，4H).ESI-MS：517.1(M-H
+，100)
Embodiment 8:1,4-pair-[3-(1,3-dioxy-3-carboxyl)-Phenoxymethyl]-benzene 2c
Step 1:1,4-pair-brooethyl-benzene (compound 8c)
In an exsiccant list neck bottle, add NBS (20.1g, 112.36mmol), (5.56mL, 45.0mmol) and the 100mL tetracol phenixin, agitation condition adds benzoyl peroxide (18mg) down to p-Xylol.System refluxed 36 hours under vigorous stirring, during room temperature the sedimentation and filtration that generates in the reaction process was fallen, and filtrate concentrates the back column chromatography, and 100% sherwood oil is made eluent, obtains 6.12g white solid compound 8c, productive rate 51.0%.
1HNMR(400MHz，CDCl
3)：δ7.37(m，4H)；4.48(s，4H).
Step 2:1,4-pair-(3-acetyl Phenoxymethyl)-benzene (compound 9c)
Under nitrogen protection, (1.36g 10.0mmol) is dissolved in the anhydrous N of 15mL, and dinethylformamide is with K with the 3-hydroxy acetophenone
2CO
3(2.76g, 20.0mmol) and compound 8c (1.056g 4.0mmol) adds in the system, system was reacted 4 hours at 60 ℃, behind the system dilute with water, and the water ethyl acetate extraction, merge organic phase, use NaOH solution and the saturated common salt water washing of 2N successively, anhydrous Na
2SO
4Dry.After organic phase concentrated, (PE: EtOAc=3: 1) purifying obtained 0.54g white solid 9c, productive rate 36.1% to the resistates column chromatography.
1HNMR(400MHz，CDCl
3)：δ7.57-7.54(m，4H)；7.47(s，4H)；7.39-7.35(t，2H)，7.19-7.16(m，2H)；5.12(s，4H)，2.58(s，6H).EI-MS(M/Z，％)：239(100)，197(18.0)，104(58.0).
Step 3:1,4-pair-[3-(1,3-dioxy-4 butyric acid methyl esters)-Phenoxymethyl]-benzene (compound 10c)
In the single neck bottle of exsiccant 25mL, add CH
3ONa (410mg, 7.59mmol) and the 4mL dry toluene, cryosel is bathed cooling, slowly drip 9c (284mg, 0.76mmol) and MeOOCCOOtBu (486mg 3.03mmol) is dissolved in the solution of THF/DME (3.0mL/3.0mLL), 0 ℃ is stirred after 0.5 hour down, under the intense agitation, reaction mixture is poured in the frozen water of HCl solution (1N) into the water dichloromethane extraction, merge organic phase, use the HCl solution of 1N successively, salt washing, anhydrous Na
2SO
4Dry.Organic phase concentrates back resistates column chromatography (CHCl
3/ CH
3OH=10: 1) purifying obtains 0.414g oily compound 10c, productive rate 100%.
1HNMR(400MHz，CDCl
3)：δ7.67-7.62(m，4H)；7.51-7.47(m，6H)；7.36-7.34(m，2H)；7.08(s，2H)；5.23(s，4H)，3.85(s，6H).
Step 4:1,4-pair-[3-(1,3-dioxy-3-carboxyl)-Phenoxymethyl]-benzene (compound 2c)
With compound 1,4-is two-and (0.163g 0.298mmol) is dissolved in the mixed solvent (1.0mL: 1.0mL) of tetrahydrofuran (THF) and methyl alcohol to [3-(1,3-dioxy-3-carboxylate methyl ester)-Phenoxymethyl]-benzene 10c, NaOH solution with 3.0mL 1N under the room temperature slowly drops in the system, stir after 1 hour, the reaction system extracted with diethyl ether, water uses the HCl adjust pH of 2N to 1-2, use ethyl acetate extraction then, merge organic phase, salt washing, anhydrous Na
2SO
4Drying.After organic phase concentrated, resistates obtained 0.107g yellow solid 2c, productive rate 69.2%. with sherwood oil/methylene dichloride recrystallization
1HNMR(400MHz，CDCl
3)：δ7.66-7.61(m，3H)；7.50-7.46(m，5H)；7.34-7.31(m，3H)；7.08(s，2H)，5.21(s，4H).ESI-MS：517.1(M-H
+，100)
Embodiment 9:1-(1,1-two [3-(1,3-dioxy-3-carboxyl)-phenyl]) methyl-2-fluoro-benzene 2d
Step 1:(3-bromo-phenyl)-(2-fluoro-phenyl)-ketone (compound 11)
With (3-bromo-phenyl)-(2-fluoro-phenyl)-methyl alcohol (compound 3) (3.84g, 13.6mmol) be dissolved in 40mL acetone, under 0 ℃ of agitation condition, slowly drop to 10.21mL Jones oxidation agent in the system, 0 ℃ was reacted 25 minutes down, the 10mL Virahol is slowly dropped in the system, remove ice bath, room temperature condition stirred 10 minutes down, the pad diatomite filtration, concentrate back column chromatography (sherwood oil: ethyl acetate=8: 1), obtain 3.757g white solid 11, productive rate 98.6%.
1HNMR(300MHz，CDCl
3)：δ7.96-7.98(m，1H)；7.71-7.76(m，2H)；7.53-7.59(m，2H)；7.29-7.38(m，2H)；7.15-7.21(m，1H).EI-MS(M/Z，％)：281(M
++3，8.0)；280(M
++2，48.0)；279(M
++1，8.0)；278(M
+，48.0)；183(28.0)；
185(23.0)；123(100).IR(film)：1658，1608，1563，1480，1453，1297，734cm
-1.
Step 2: two-(3-bromo-phenyl)-(2-fluoro-phenyl)-methyl alcohol (compound 12)
Under nitrogen protection; n-Butyl Lithium hexane solution (the 6.5mL that in a dry reaction bottle, adds 1.6M; 10.4mmol) and the 35mL anhydrous tetrahydro furan, be chilled to-78 ℃, with 1; 3-dibromobenzene (2.28mL; 18.85mmol) slowly drop in the system ,-78 ℃～-50 ℃ were stirred after 3.5 hours, will be dissolved in the compound 11 (3.757g of 5mL anhydrous tetrahydro furan; 13.46mmol) slowly drop in the system, make system temperature be lower than-50 ℃.-78 ℃～-50 ℃ were stirred 0.5 hour, were warming up to room temperature naturally and continued reaction after 3 hours, the saturated NH of system
4The cancellation of Cl solution, the water extracted with diethyl ether merges organic layer, uses saturated NaHCO successively
3Solution is washed, saturated salt washing, anhydrous Na
2SO
4Dry.After concentrating, column chromatography (petrol ether/ethyl acetate=40: 1) purifying gets 5.58g white solid 12, productive rate 95%.
1HNMR(300MHz，CDCl
3)：δ7.50-7.67(m，4H)；7.25-7.34(m，4H)；6.96-7.08(m，3H)；6.67-6.68(m，1H).EI-MS(M/Z，％)：436(M
+，8.43)；281(39.40)；279(40.35)；185(17.84)；183(22.30)；123(100)；95(21.70)；57(15.23).IR(film)：υ
max3481，3419，1610，1580，1564，1550，1485，1452，1420，1227，760cm
-1.
Step 3:1-[1,1-two (3-bromo-phenyl)]-methyl-2-fluoro-benzene (compound 13)
With compound 12 (5.58g, 12.79mmol) and sodium iodide (7.67g, 51.16mmol) be dissolved in the 35mL acetonitrile, after the stirring and dissolving, and slow dropping dimethylchlorosilane in system (3.08mL, 25.59mmol), stirring at room 2 hours, system washes saturated NaHCO with water after diluting with ethyl acetate successively
3Solution, 10% Na
2S
2O
3Solution and salt washing, anhydrous Na
2SO
4Drying.After concentrating, column chromatography (100% sherwood oil) gets 5.37g white solid 13, productive rate 100%.
1HNMR(400MHz，CDCl
3)：δ7.39-7.36(m，2H)；7.35-7.13(m，5H)；7.12-7.01(m，4H)；6.91-6.86(m，1H)；5.74(s，1H)；EI-MS(M/Z，％)：418(M
+，30.0)；420(M
++2，55.7)；422(M
++4，29.8)；341(76.0)；339(72.4)；183(100)；165(55.0).
Step 4:1-[1,1-two (3-acetyl phenyl)]-methyl-2-fluoro-benzene (compound 14)
With compound 13 (1.049g, 2.497mmol) be dissolved in the 10mL anhydrous tetrahydro furan, be chilled to-78 ℃, n-Butyl Lithium hexane solution (3.9mL with 1.6M, 6.244mmol) slowly drop in the system ,-78 ℃ were stirred 45 minutes, with N-methyl-N-methoxyl group ethanamide (0.7mL, 6.244mmol) slowly drop in the system, make system temperature be lower than-50 ℃.-78 ℃～-50 ℃ were stirred 0.5 hour, were warming up to room temperature naturally and continued reaction after 2 hours, the saturated NH of reaction
4The cancellation of Cl solution, extracted with diethyl ether merges organic layer, uses saturated NaHCO successively
3Solution is washed, saturated salt washing, anhydrous Na
2SO
4Drying.After concentrating, column chromatography (petrol ether/ethyl acetate=10: 1) gets 0.522g white solid 14, productive rate 40.2%.
1HNMR(400MHz，CDCl
3)：δ7.86-7.83(dt，2H)；7.74-7.73(m，2H)；7.43-7.40(t，2H)；7.30-7.24(m，3H)；7.10-7.04(m，2H)；6.91-6.87(td，1H)；5.94(s，1H)；2.55(s，6H).
Step 5:1-(1,1-two [3-(1,3-dioxy-3-carboxyl)-phenyl]) methyl-2-fluoro-benzene 2d
In the single neck bottle of exsiccant 25mL, add CH
3ONa (146mg, 2.7mmol) and 2mL dry toluene, will be dissolved in the time of 0 ℃ 2.0mL/2.0mL (THF/DME) compound 14 (94mg, 0.27mmol) and MeOOCCOOtBu (173mg, 1.08mmol) slowly drop in the system, 0 ℃ is stirred after 0.5 hour, under the intense agitation, reaction mixture is poured in cold HCl (1N) solution, the water dichloromethane extraction, merge organic phase, wash anhydrous Na with HCl solution, the salt of 1N successively
2SO
4Drying.Organic phase obtains oily compound 15 after concentrating, and without purification, continues next step reaction.Compound 15 is dissolved in 2.0mL/2.0mL (THF/CH
3OH), (5.0mL 5.0mmol) slowly drops in the system, and stirring at room is after 1 hour with the NaOH solution of 1N during room temperature, system extracted with diethyl ether, water use the HCl solution adjust pH of 2N to 1-2, use ethyl acetate extraction then, merge organic phase, salt washing, anhydrous Na
2SO
4Drying.After organic phase concentrated, resistates obtained yellow compound 2d (86mg, two step yields 65%) with sherwood oil/methylene dichloride recrystallization.
1HNMR(400MHz，CDCl
3)：δ7.92-7.80(m，4H)；7.49-7.45(m，3H)；7.35-7.35(m，5H)；7.12-6091(m，3H)；7.00(s，1H)；6.09(s，1H).
ESI-MS：489.1(M-H
+，100).
Claims (8)
1, the beta-diketon acid dimer compound that has following structure
Wherein, X is N, O, S heteroatoms;
R is C
2-C
6Alkyl, C
2-C
6Substituted aryl;
R
1Be C
2-C
6Alkyl, C
2-C
6Substituted aryl;
2, beta-diketon acid dimer compound according to claim 1 is characterized in that when structure during as the beta-diketon acid dimer compound of (1) formula, wherein
X is N, O, S heteroatoms;
R is C
2-C
6Alkyl, C
2-C
6Substituted aryl;
R
1Be C
2-C
6Alkyl, C
2-C
6Substituted aryl;
3, beta-diketon acid dimer compound according to claim 1 is characterized in that when structure during as the beta-diketon acid dimer compound of (2) formula, wherein
X is N, O, S heteroatoms;
R is C
2-C
6Alkyl, C
2-C
6Substituted aryl;
R
1Be C
2-C
6Alkyl, C
2-C
6Substituted aryl;
4, beta-diketon acid dimer compounds process for production thereof according to claim 1, it is characterized in that (1) formula by
A, corresponding aryl methyl ketone and dimethyl oxalate or oxalic acid tert-butyl ester methyl esters react under the alkali condition, and condenses caustic liquor again solves 4-aryl-4 oxygen-2-hydroxyl-2 butenoic acid;
B, with the diamines of the butenoic acid of above-mentioned gained and different structure in the presence of coupling reagent, coupling becomes to have the different carbon chain lengths or the difform two ketone acid diamide of symmetrical structure.
5, beta-diketon acid dimer compounds process for production thereof according to claim 1, it is characterized in that (2) formula by
To be starting raw material generate dibromomethylbenzene through N-bromo-succinimide bromination for a, dimethylbenzene, dibromomethylbenzene and 3-hydroxy acetophenone under alkaline condition, react two phenyl ethyl ketones of benzyloxy connection;
B, with two phenyl ethyl ketones of above-mentioned gained after oxalylization, hydrolysis gets two accordingly aryl diketone acid dimers again.
6, beta-diketon acid dimer compounds process for production thereof according to claim 1, it is characterized in that (2) formula by
A, (3-bromo-phenyl)-(substituted-phenyl)-methyl alcohol are oxidized to corresponding ketone through Jones reagent;
B, corresponding ketone and substituted-phenyl lithiumbromide react the trimethyl carbinol of triaryl replacement;
C, the above-mentioned and trimethyl carbinol through dichlorodimethylsilane reduce two-(3-bromophenyl)-arylmethane accordingly;
D, corresponding diaryl ketone-aryl-methane carry out oxalylization react reactant separate with caustic liquor that to be able to the methane that aryl replaces be two aryl two ketone dimers of connector element.
7, beta-diketon acid dimer compounds process for production thereof according to claim 4 is characterized in that coupling reagent is I-hydroxybenzotriazole (HOBT), 1-[3-(dimethylamino) propyl group]-3-ethyl carbodiimide (EDCI).
8, the purposes of beta-diketon acid dimer compound as claimed in claim 1 is characterized in that it uses in the prevent and treat AIDS-treating medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03116758 CN1548413B (en) | 2003-05-06 | 2003-05-06 | Beta-diketoacid as dimer compound and its prepn and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03116758 CN1548413B (en) | 2003-05-06 | 2003-05-06 | Beta-diketoacid as dimer compound and its prepn and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1548413A true CN1548413A (en) | 2004-11-24 |
| CN1548413B CN1548413B (en) | 2011-09-21 |
Family
ID=34320468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03116758 Expired - Fee Related CN1548413B (en) | 2003-05-06 | 2003-05-06 | Beta-diketoacid as dimer compound and its prepn and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1548413B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102234231A (en) * | 2010-04-26 | 2011-11-09 | 中国科学院上海药物研究所 | 1-substituted-2-substituted-4- aryl substituted-butyl-2-alkene 1, 4-diketone compound, its preparation method and application |
| CN102406634A (en) * | 2010-09-21 | 2012-04-11 | 中国医学科学院医药生物技术研究所 | Human immunodeficiency virus (HIV)-1 integrase inhibitor |
| CN111253223A (en) * | 2020-03-20 | 2020-06-09 | 重庆医科大学 | Triarylmethane derivatives with large steric hindrance and synthesis method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0111570A (en) * | 2000-06-16 | 2003-09-09 | Bristol Myers Squibb Co | Hiv integrase inhibitors |
-
2003
- 2003-05-06 CN CN 03116758 patent/CN1548413B/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102234231A (en) * | 2010-04-26 | 2011-11-09 | 中国科学院上海药物研究所 | 1-substituted-2-substituted-4- aryl substituted-butyl-2-alkene 1, 4-diketone compound, its preparation method and application |
| CN102234231B (en) * | 2010-04-26 | 2015-01-07 | 中国科学院上海药物研究所 | 1-substituted-2-substituted-4- aryl substituted-butyl-2-alkene 1, 4-diketone compound, its preparation method and application |
| CN102406634A (en) * | 2010-09-21 | 2012-04-11 | 中国医学科学院医药生物技术研究所 | Human immunodeficiency virus (HIV)-1 integrase inhibitor |
| CN102406634B (en) * | 2010-09-21 | 2015-09-30 | 中国医学科学院医药生物技术研究所 | Hiv-1 integrase inhibitor |
| CN111253223A (en) * | 2020-03-20 | 2020-06-09 | 重庆医科大学 | Triarylmethane derivatives with large steric hindrance and synthesis method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1548413B (en) | 2011-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1026322C (en) | Benzoxazole derivative and processes for preparing same | |
| CN1309704C (en) | Anthranyl amides and their use as medicaments | |
| CN1178658C (en) | Process for synthesizing Cox-2 inhibitors | |
| CN1285578C (en) | Substituted benzoic acid amides and use for inhibition of angiogenesis thereof | |
| CN1308326C (en) | Process for preparing indolinone derivatives | |
| CN1134415C (en) | Process for making diaryl pyridines useful as cox-2 inhibitors | |
| CN1137103C (en) | Method for producing triazolinthion derivatives | |
| CN1324017C (en) | Process for preparing 5-(1, 3-oxazol-2-yl) benzoic acid derivatives | |
| CN1802154A (en) | Pyridine N-oxides as antiviral agents | |
| CN1927830A (en) | Compound of optically pure sulfenamides and application thereof | |
| CN1274348A (en) | Method for producing triazolinethione derivatives | |
| CN1826335A (en) | Process for producing 1,2,4-triazole compound and intermediate therefor | |
| CN1166629C (en) | Benzene sulfonamide compounds, its preparing method and medicinal compsns. contg. same | |
| CN1229347C (en) | Process for production of piperidine derivative fexofenadine | |
| CN1548413A (en) | Beta-diketoacid as dimer compound and its prepn and use | |
| CN1159318C (en) | Metal protease inhibitor, preparing process thereof and pharmaceutical composition contg. same | |
| CN101054355A (en) | Compound of optically pure disulfenamides and application thereof | |
| CN1086809A (en) | 5-oxo-dibenzo [a, d] ring heptan-1, the 4-diene | |
| CN1370151A (en) | Process for preparing 2-amino-4-(4-fluorophenyl)-6-alkylpyrimidine-5-carboxylate | |
| CN1968941A (en) | Method for producing 3-aminomethyltetrahydrofuran derivative | |
| CN1168715C (en) | Novel benzene amine compound, its prepn. process and medicinal compsns. contg. them | |
| CN87107427A (en) | The aminomethyl-5,6,7 that replaces, 8-naphthane oxo acetate, new midbody product, their preparation process and as the application of medicine | |
| CN1231482C (en) | Processes for the preparation of thiazolidinedione derivatives and intermediates | |
| CN1268119A (en) | Process for preparing 4-substituted-1H-indole-3-glyoxamides | |
| CN1244573C (en) | Benzofuran category compound, its preparing method and usage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20041124 |
|
| CI01 | Publication of corrected invention patent application |
Correction item: Rejection of patent application Correct: Dismiss False: Reject Number: 32 Volume: 26 |
|
| ERR | Gazette correction |
Free format text: CORRECT: PATENT APPLICATION REJECTION AFTER PUBLICATION; FROM: REJECTION TO: REJECTION OF REVOCATION |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110921 Termination date: 20150506 |
|
| EXPY | Termination of patent right or utility model |